Navigation Links
Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day
Date:3/4/2009

ALISO VIEJO, Calif., March 4 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has rescheduled the release of its financial results for the fourth quarter and year-ended December 31, 2008 to Wednesday, March 11th in order to complete its year end audit and to more closely coincide with the filing of its Form 10-K for the year ended December 31, 2008.

    Date: Wednesday, March 11, 2009

    Start Time: 5:00 pm EDT

    Call-in Number: 1-800-762-8779
                    (International) 480-248-5081

    Conference ID Number: 3992520

    Webcast: www.clarientinc.com/investor

    Web Replay: For those unable to participate during the live broadcast,
    the webcast replay will be archived at www.clarientinc.com/investor
    shortly after the call and will be available for one year.

    Speakers: Ron Andrews, Vice Chairman and CEO; Dr. Mike Pellini, President
    and COO; Ray Land, CFO

    Format: Discussion of fourth quarter and year-end 2008 financial results
    followed by Q&A

About Clarient

Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

About Safeguard Scientifics

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com

    CONTACT:

    Allen & Caron Inc.
    Matt Clawson
    949.474.4300
    matt@allencaron.com


'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Clarient Renews and Expands Mezzanine Credit Facility With Safeguard
2. Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays
3. Clarient Reports First Quarter 2008
4. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
5. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
6. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
7. Clarient Generates 52% Revenue Increase in Third Quarter 2007
8. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
9. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
10. Clarient to Present at the UBS 2007 Global Life Sciences Conference
11. Cell Therapeutics Reschedules Special Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations ... Rory Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s ... ) today reported on a new study released on May 21, 2017 in the ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, the ... month as a Guest Speaker and Contributor to a weeklong series of classes, meetings, ... , Walter Schindler and SAIL Capital have received an ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... patients on peri-implantitis in Las Vegas, NV, and the importance of ... gum disease consultation and leading care for peri-implantitis, with or without a referral. ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... New patients ... Kevin Hogan, an experienced dentist practicing in Mt. Pleasant, SC, with or without a ... often recommended for patients with missing teeth in Charleston, SC. Those who ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... now receive treatment using the SPEED System™ Orthodontics, with or without a referral, ... orthodontist in El Segundo, CA, who is skilled in providing patients with ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
(Date:5/3/2017)... May 3, 2017 A Catheterization Laboratory ... or healthcare facility. Commonly referred to as cath ... with diagnostic imaging technology to give physicians visual ... In these spaces, a team of physicians perform ... percutaneous coronary intervention, congenital heart defect closure, stenotic ...
(Date:5/3/2017)... , May 3, 2017  Getinge, a leading ... to quality enhancement and cost efficiency within healthcare ... study of contemporary practice demonstrating that intra-aortic balloon ... for critically ill patients. The single-center, retrospective, observational ... large volume MEGA ® 50cc intra-aortic balloon ...
Breaking Medicine Technology: